Targeting Myocardial Mitochondria-STING-Polyamine Axis Prevents Cardiac Hypertrophy in Chronic Kidney Disease

Area of Science:

• Cardiovascular Research
• Nephrology
• Molecular Biology

Background:

• Chronic kidney disease (CKD) is a known risk factor for cardiac hypertrophy.
• The precise molecular mechanisms linking CKD to cardiac hypertrophy are not fully understood.

Purpose of the Study:

• To elucidate the role of myocardial mitochondrial oxidative damage and the STING-NFκB pathway in CKD-associated cardiac hypertrophy.
• To identify novel therapeutic targets for preventing cardiac hypertrophy in CKD.

Main Methods:

• Investigated myocardial mitochondrial oxidative damage in CKD models.
• Analyzed the activation of the STING-NFκB pathway and its downstream targets.
• Assessed the role of ornithine decarboxylase (ODC1) and putrescine metabolism.
• Utilized genetic and pharmacologic inhibition strategies.

Main Results:

• Myocardial mitochondrial oxidative damage and DNA release are early and prominent in CKD, activating the STING-NFκB pathway.
• The STING-NFκB pathway stimulates cardiac hypertrophy by transactivating ODC1-putrescine metabolic flux.
• Inhibition of the mitochondria-STING-NFκB-ODC1 axis significantly ameliorates CKD-induced cardiac hypertrophy.

Conclusions:

• Myocardial mitochondrial damage-induced STING-NFκB activation, coupled with ODC1-putrescine metabolism, is a key driver of cardiac hypertrophy in CKD.
• Targeting the mitochondria-STING-NFκB-ODC1 axis represents a promising therapeutic strategy for CKD-associated cardiac hypertrophy.